Epigenetic Coordination in MZF1 Splicing and EGFR-TKI Resistance

Study Background and Research Question

Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with the majority of cases driven by mutations in the epidermal growth factor receptor (EGFR) gene. The introduction of EGFR tyrosine kinase inhibitors (EGFR-TKIs) has significantly improved outcomes for patients harboring such mutations. However, acquired resistance to these targeted therapies severely limits their long-term efficacy. While previous studies have largely focused on genetic mutations underpinning resistance, accumulating evidence suggests that epigenetic modifications—dynamic and potentially reversible changes in gene regulation—also play a substantial role in this process. The present study by Zhang et al. (Experimental & Molecular Medicine, 2026) addresses a fundamental question: How do epigenetic modifications, specifically DNA 5-methylcytosine (5-mC) and RNA 5-methylcytosine (m5C) methylation, coordinate to regulate alternative splicing of the myeloid zinc finger 1 (MZF1) gene, and how does this regulation contribute to EGFR-TKI resistance in NSCLC?

Key Innovation from the Reference Study

The most significant innovation of this work lies in its identification of a dual-layer epigenetic mechanism that governs the alternative splicing of MZF1, ultimately modulating EGFR-TKI resistance. Specifically, the authors reveal that both DNA 5-mC and RNA m5C methylation modifications converge at overlapping loci within the 5′-untranslated region (UTR) of MZF1. This combinatorial regulation not only influences transcriptional activity but also impacts post-transcriptional alternative splicing events. The study further characterizes a UHRF1/DNMT1-NSUN7/YBX1 axis, which synergistically determines the selection between two MZF1 splice variants with divergent functional roles in drug resistance. This work establishes a conceptual framework for how epigenetic marks across different nucleic acid substrates can orchestrate complex gene regulatory outcomes relevant to cancer therapy.

Methods and Experimental Design Insights

To dissect the interplay between DNA and RNA methylation in MZF1 splicing, the authors employed a combination of clinical cohort analysis, molecular biology techniques, and functional assays:

• Clinical sample profiling: Tumor specimens from patients with EGFR-TKI-sensitive and -resistant NSCLC were analyzed for MZF1 splice variant expression and methylation status.
• Methylation mapping: Bisulfite sequencing and RNA methylation profiling were used to map DNA 5-mC and RNA m5C modifications at the MZF1 5′-UTR.
• Splicing factor analysis: The roles of SRSF1 and SRSF3 in MZF1 pre-mRNA processing were interrogated via RNA-immunoprecipitation and competitive binding assays, investigating how m5C methylation alters splicing factor recruitment.
• Functional validation: Knockdown and overexpression experiments targeting the UHRF1/DNMT1-NSUN7/YBX1 axis assessed the impact on MZF1 splice variant expression and EGFR-TKI sensitivity.
• Zn²⁺ homeostasis and EGFR phosphorylation: Biochemical assays quantified zinc binding and EGFR activation state in relation to MZF1 isoform predominance.

This comprehensive multi-omics and functional workflow allowed the authors to mechanistically link epigenetic regulation, alternative splicing, and downstream cellular phenotypes relevant to drug resistance.

Core Findings and Why They Matter

The study's main findings reshape the understanding of EGFR-TKI resistance mechanisms:

• Splice variant divergence: Two major MZF1 isoforms exist: MZF1L (long), which retains intact zinc finger domains, and MZF1S (short), which lacks the C2H2 zinc finger and exhibits diminished Zn²⁺-binding capacity. MZF1L predominates in EGFR-TKI-sensitive tumors, while MZF1S is enriched in resistant cases (reference study).
• Epigenetic control of splicing: Overlapping DNA 5-mC and RNA m5C modifications at the MZF1 5′-UTR serve as a regulatory hub, influencing recruitment of splicing factors SRSF1 and SRSF3. NSUN7/YBX1-mediated m5C methylation promotes SRSF1 binding, favoring MZF1S production, while coordinated action with the DNA methylation machinery (UHRF1/DNMT1) reinforces this bias.
• Functional consequence: MZF1L suppresses EGFR phosphorylation and internalization by maintaining zinc homeostasis, thereby supporting EGFR-TKI sensitivity. In contrast, MZF1S fails to maintain Zn²⁺ balance, permitting ligand-independent EGFR activation and resistance.
• Therapeutic implication: Targeting the UHRF1/DNMT1-NSUN7/YBX1 axis suppresses MZF1S and restores MZF1L, resensitizing resistant NSCLC cells to EGFR-TKIs, and suggesting methylation-regulated splice variants as both biomarkers and actionable targets.

These discoveries emphasize that resistance to targeted therapy is not solely a function of genetic mutation, but also of dynamic, reversible epigenetic events that modulate gene expression and protein function at multiple regulatory levels.

Comparison with Existing Internal Articles

The integrative epigenetic model presented by Zhang et al. contrasts with the experimental paradigms discussed in several internal resources focused on nephrology:

• The article "Puromycin Aminonucleoside: Mechanistic Insights and Novel..." reviews the role of the aminonucleoside moiety of puromycin in podocyte injury models and transporter-mediated uptake. While this work elucidates mechanisms of nephrotoxicity and podocyte dysfunction, it does not address epigenetic splicing regulation or resistance in oncology settings.
• Similarly, "Puromycin Aminonucleoside: Precision for Podocyte Injury Models" provides protocols for reproducible glomerular lesion induction and proteinuria in animal models, leveraging puromycin aminonucleoside's unique action on podocyte morphology. This is conceptually related in terms of mechanistic modeling, but differs in biological context and regulatory focus.

Whereas these internal articles emphasize the utility of puromycin aminonucleoside for modeling nephrotic syndrome and podocyte injury, the current reference study focuses on epigenetic mechanisms in cancer drug resistance, highlighting the diversity of molecular control points across research domains.

Limitations and Transferability

While the study robustly characterizes the UHRF1/DNMT1-NSUN7/YBX1 axis in MZF1 splicing and EGFR-TKI resistance, several limitations should be noted:

• Cohort size and diversity: The findings are derived from defined clinical cohorts, and their generalizability across broader NSCLC populations requires further validation.
• Model specificity: The mechanistic insights are currently specific to EGFR-mutant NSCLC and may not extrapolate to other tumor types or resistance mechanisms without additional evidence.
• Functional redundancy: Other epigenetic or splicing factors may also contribute to resistance phenotypes, and the interplay among these regulators remains to be fully mapped.
• Translational maturity: While targeting the epigenetic axis resensitizes resistant cells in vitro, translation to clinical interventions will require the development of selective and safe modulators of these pathways.

Despite these constraints, the conceptual advance in linking coordinated DNA and RNA methylation with alternative splicing and drug resistance signals a promising avenue for future research.

Protocol Parameters

• Methylation mapping: Use bisulfite sequencing for DNA 5-mC mapping; employ RNA immunoprecipitation and m5C-specific antibodies for RNA methylation profiling.
• Splicing assays: Implement RT-PCR with isoform-specific primers to quantify MZF1L and MZF1S transcripts in cell and tissue samples.
• Splicing factor manipulation: Transfect cells with siRNA or CRISPR constructs targeting SRSF1, SRSF3, NSUN7, UHRF1, or DNMT1 as appropriate, to experimentally modulate the splicing axis.
• Functional validation: Assess EGFR phosphorylation status via Western blot after experimental manipulation of the MZF1 splicing machinery.
• Resistance modeling: Develop EGFR-TKI-resistant NSCLC lines by chronic drug exposure, allowing for dynamic study of epigenetic and splicing changes over time.

Research Support Resources

For researchers aiming to model nephrotoxic injury or study the cellular consequences of podocyte damage, Puromycin aminonucleoside (SKU A3740) can be utilized as a well-characterized tool compound. The aminonucleoside moiety of puromycin induces podocyte injury and glomerular lesions, supporting the establishment of proteinuria-based animal models and in vitro cytotoxicity assays, as reported in the product information. While the experimental context differs from the epigenetic regulation of therapy resistance described above, integrating such standardized reagents helps ensure reproducibility and mechanistic clarity in renal and cellular pathology workflows.